TNF-alpha inhibitor is

Correct Answer: Infliximab
Description: (A) Infliximab [Harrison18-2491; G&G12-1018; Il,h-I419;# ANTI-TNF-ALPHA INHIBITORS:> Adalimumab, etanercept, and infliximab are antibodies that bind TNF alfa a proinflammatory cytokine.> Blocking TNF alfa from binding to TNF receptors on inflammatory cell surfaces results in suppression of downstream inflammatory cytokines such as IL-1 and IL-6 and adhesion molecules involved in leukocyte activation and migration.> An increased risk of lymphoma is common to each of these agents.> Infliximab is a human-mouse chimeric lgG1 monoclonal antibody possessing human constant (Fc) regions and murine var able regions.> Infliximab is currently approved for use in Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.> Efalizumab is a recombinant humanized anti-CD11 a monoclonal antibody approved for the treatment of adult patients with severe psoriasis.> Binding of Efalizumab to CD11a (the alpha subunit of LFA-1) inhibits the interaction of LFA-1 on all lymphocytes with intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion, activation, and migration of lymphocytes into skin.> Efalizumab is administered by subcutaneous injection.Infliximab is a monoclonal antibody against TNF. It is used to treat autoimmune diseases.> Decorin & Mannose-6-phosphates are TGF-beta inhibitors.
Category: Pharmacology
Share:

Get More
Subject Mock Tests

Practice with over 200,000 questions from various medical subjects and improve your knowledge.

Attempt a mock test now
Mock Exam

Take an exam with 100 random questions selected from all subjects to test your knowledge.

Coming Soon
Get More
Subject Mock Tests

Try practicing mock tests with over 200,000 questions from various medical subjects.

Attempt a mock test now
Mock Exam

Attempt an exam of 100 questions randomly chosen from all subjects.

Coming Soon
WordPress › Error

There has been a critical error on this website.

Learn more about troubleshooting WordPress.